Presentation of the ENDO-SFOG CAMPUS app: An easy therapeutic decision support app in endometrial cancer created by the French Society of Young Gynecological Oncologists (SFOG Campus) - 03/04/25

Doi : 10.1016/j.jogoh.2025.102951

Virginie Collin-Bund ^1,^2,^⁎ , Floriane Jochum ³, François Margueritte ⁴, Thomas Gaillard ³, Morgane Perrin ⁵, Yohan Kerbage ⁶, Renaud Sabatier ⁷, Anne Thoury ⁸, Sarah Betrian ⁹, Guillaume Babin ¹⁰, Basile Pache ¹¹, Phuong Lien Tran ¹², Noémie Body ¹³, Julie Delvallee ¹⁴, Houssein El Hajj ¹⁵, Frederic Guyon ¹⁰, Emilie Raimond ¹⁶, Chérif Akladios ¹, Enora Laas ³, Elise Deluche ¹⁷
the SFOG CAMPUS group
¹ Gynecology and Obstetrics Department, Hopitaux Universitaires de Strasbourg, Strasbourg, France
² Laboratoire d'ImmunoRhumatologie Moléculaire, Institut National de la Santé et de la Recherche Médicale (INSERM) UMR_S 1109, Institut thématique interdisciplinaire (ITI) de Médecine de Précision de Strasbourg, Transplantex NG, Faculté de Médecine, Fédération Hospitalo- universitaire OMICARE, Fédération de Médecine Translationnelle de Strasbourg (FMTS)Université de Strasbourg, Strasbourg, France
³ Surgery Department, Institut Curie, University Paris Cite, 75005 Paris, France
⁴ Gynecology and Obstetrics Department, Hospital Center of Poissy Saint Germain en Laye, Poissy, France
⁵ Gynecology Department, Gustave Roussy Institute, Villejuif, France
⁶ Department of Gynaecology and Obstetrics,CHRU Lille, F-59000 Lille, France
⁷ Department of Medical Oncology, Aix-Marseille Univ, Inserm, CNRS, Institut Paoli-Calmettes, 232 Boulevard Sainte Marguerite, Marseille, France
⁸ Gynecology Department, Hôpital Hôtel-Dieu de Paris, France
⁹ Medical Oncology Department, IUCT Oncopole, 31059 Toulouse, France
¹⁰ Surgical Oncology Department, Bergonié Institute, 33076 Bordeaux, France. ARTiSt Lab, Univ. Bordeaux, INSERM U1312, F-33000 Bordeaux, France
¹¹ Gynecology Department, Hôpital Cantonal hôpital fribourgeois (HFR) Fribourg, Switzerland
¹² Gynecology and Obstetrics Department, Centre Hospitalier Universitaire (CHU) Sud La Réunion, Avenue du Président Mitterrand, BP350, 97448 Saint Pierre, La Reunion, France
¹³ Gynecology Department, Hôpital Anne de Bretagne, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France
¹⁴ Department of Gynaecology, Centre Hospitalier Universitaire de Tours, Tours, France
¹⁵ Léon Bérard Center, Lyon, France
¹⁶ Gynecology and Obstetrics Department, Champagne Sud Hospital, Troyes, France
¹⁷ Oncology Department, University Hospital, Limoges, France

^⁎Corresponding author: Virginie Collin-Bund.

Sous presse. Manuscrit accepté. Disponible en ligne depuis le Thursday 03 April 2025

Abstract

Objective

: This study evaluates a new decision support tool—a computer/mobile application designed to align with the latest ESGO guidelines, French practices, and molecular biology data—to aid in decision-making for endometrial cancer management.

Methods

: An observational, multicenter, retrospective study was conducted. It compared management decisions from multidisciplinary tumor boards (MTBs) with those suggested by the application for patients with histologically confirmed endometrial cancer, irrespective of their FIGO stage. Each center included the last 20 cases discussed in multidisciplinary tumor boards between May to December 2022.

Results

Thirteen centers participated: eight university hospitals (61.5%), four cancer centers (30.8%), and one private center (7.7%). A total of 259 patients were included, with a mean age of 69 years (range 30−96 years). Most patients had endometrioid tumors (77.2%), low-grade (62.6%), FIGO stage IA (41.3%), no lymphovascular invasion (77.9%), and a non-specific molecular profile (50.6%). The application's recommendations matched the MTB decisions 76.6% of the time. Discrepancies arose mainly from the non-administration of brachytherapy (22.8%), rare presentations or pathological discordance (22.8%), and patients' deteriorated conditions precluding standard treatments (19.3%).

Conclusion

: The SFOG campus application demonstrates a high concordance with multidisciplinary tumor board decisions, indicating its potential as an efficient, and valuable tool for managing endometrial cancer.

Le texte complet de cet article est disponible en PDF.

Keywords : Endometrial Neoplasms, Practice Guidelines, Computer Applications, Molecular Biology, Tumor Board